Skip to main content

PredictImmune Inks Multinational Commercialization Pact for IBD Test

NEW YORK — PredictImmune said on Tuesday that it has signed an agreement for promotion and distribution of its PredictSure IBD test in the UK, Ireland, the Middle East, and the Balkans with Cambridge Clinical Laboratories (CCL).

PredictSure IBD is a PCR-based test is designed to analyze the expression of 17 genes in whole blood in order to differentiate mild and aggressive forms of Crohn's disease and ulcerative colitis and to guide treatment options.

Under the terms of the agreement, Cambridge, England-based CCL will oversee PredictSure IBD order fulfillment, as well as receive and process test samples, on a nonexclusive basis in the UK and Ireland and exclusively in the Middle East and Balkans.

Additional terms were not disclosed.

"This latest partnership will enable increasing numbers of patients across the UK and Ireland, as well as further afield, to access PredictSure IBD and gain a greater understanding of the likely course of their disease and how best to manage it," PredictImmune CEO Paul Kinnon said in a statement.

In October, PredictImmune signed deals for the commercialization of PredictSure IBD in French-speaking countries in Europe and Africa with Theradiag, and in North America with KSL Biomedical.

UK-based PredictImmune also began working with the Crohn's & Colitis Foundation late last year to validate PredictSure IBD test in a diverse patient population.